Valeant Issues Statement On Sales Of Company Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharma (VRX) Sees 'Dead Cat Bounce' after CEO Hit with Margin Call
November 6, 2015 12:19 PM ESTValeant Pharma (NYSE: VRX) is pushing to the highs of the session, following earlier news that about 1.3 million shares CEO Mike Pearson had pledged on a loan were sold yesterday due to margins calls.
The news suggests that some of the... More
Valeant Pharma (VRX) 1.3M Shares Pledged on Behalf of Pearson Sold by Goldman Sachs
November 6, 2015 8:03 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) stated today that 1,297,399 shares pledged to Goldman Sachs to secure loans made to chairman and chief executive officer J. Michael Pearson were sold by Goldman Sachs on November 5, 2015. Goldman Sachs held the shares as collateral for loans extended to Pearson.
As disclosed in the company's proxy statement filed on April 22, 2014, the company's board permitted... More
